abusesaffiliationarrow-downarrow-leftarrow-rightarrow-upattack-typeburgerchevron-downchevron-leftchevron-rightchevron-upClock iconclosedeletedevelopment-povertydiscriminationdollardownloademailenvironmentexternal-linkfacebookfiltergenderglobegroupshealthC4067174-3DD9-4B9E-AD64-284FDAAE6338@1xinformation-outlineinformationinstagraminvestment-trade-globalisationissueslabourlanguagesShapeCombined Shapeline, chart, up, arrow, graphLinkedInlocationmap-pinminusnewsorganisationotheroverviewpluspreviewArtboard 185profilerefreshIconnewssearchsecurityPathStock downStock steadyStock uptagticktooltiptwitteruniversalityweb

Diese Seite ist nicht auf Deutsch verfügbar und wird angezeigt auf English


2 Sep 2022

Matt Fortin, NBC Boston (USA)

USA: Johnson & Johnson settles New Hampshire opioid lawsuit for $40.5 million

"Settlement Reached in New Hampshire Opioid Case Against Johnson & Johnson", 1 Sep 2022

New Hampshire has reached a settlement with Johnson & Johnson in the state's opioid case against the pharmaceutical company, four years after an initial complaint was filed.

In a news release from Attorney General John Formella's office, authorities say New Hampshire has reached a $40.5 million settlement with J&J subsidiary Janssen Pharmaceuticals. $31.5 million of that money is set to go toward fighting the opioid crisis, the release said.

"As part of our continued efforts to battle the opioid epidemic, New Hampshire is a leader in ensuring that the companies who played a role in perpetuating this crisis are held accountable for their actions," Governor Chris Sununu said in the release...

New Hampshire's Attorney General filed a complaint in 2018 against Janssen Pharmaceuticals and Ortho-McNeil-Janssen Pharmaceuticals, both of which are subsidiaries of J&J. The complaint makes a series of allegations against the drugmaker relating to its marketing of opioids in the state. One of those allegations was that the company "targeted particularly vulnerable populations," including elderly people, in its marketing of the addictive drug class...